• Dipeptidyl peptidase-4 (DPP-4) inhibitors play a vital role in the treatment of diabetes.
• Glycosylated hemoglobin (HbA1c) lowering of DPP-4 inhibitors is intermediate when compared to other agents; therefore, it is not considered a first-line therapy.
• Adverse effects, especially hypoglycemia, are limited.
• DPP-4 inhibitors in combination with metformin are generally well tolerated.
• Outcomes studies for DPP-4 inhibitors are lacking.